We are live on ! Find out more
XBIT icon

XBiotech
XBIT

45 hedge funds and large institutions have $11.1M invested in XBiotech in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 17 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.99% less ownership

Funds ownership: 11.04% → 10.05% (-0.99%)

20% less funds holding

Funds holding: 56 → 45 (-11)

29% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 17

41% less capital invested

Capital invested by funds: $18.9M → $11.1M (-$7.84M)

69% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 16

Holders
45
Holders Change
-11
Holders Change %
-19.64%
% of All Funds
0.78%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
12
Reduced
17
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
+$482K
2
Renaissance Technologies
Renaissance Technologies
New York
+$362K
3
CS
Credit Suisse
Switzerland
+$177K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$177K
5
RC
RBF Capital
California
+$109K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$691K
2
Citadel Advisors
Citadel Advisors
Florida
-$455K
3
Morgan Stanley
Morgan Stanley
New York
-$417K
4
E
Ergoteles
New York
-$395K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$380K
Name Holding Trade Value Shares
Change 		Change in
Stake
Man Group
26
Man Group
United Kingdom
$63K +$81.4K +17,300 New
TNB
27
Thomasville National Bank
Georgia
$48K – – –
Qube Research & Technologies (QRT)
28
Qube Research & Technologies (QRT)
United Kingdom
$46K -$8.46K -1,798 -12%
SF
29
Synovus Financial
Georgia
$43K – – –
JP Morgan Chase
30
JP Morgan Chase
New York
$40K -$17.3K -3,672 -25%
Charles Schwab
31
Charles Schwab
California
$38K – – –
Jane Street
32
Jane Street
New York
$38K +$49.1K +10,439 New
LFM
33
LGT Fund Management
Liechtenstein
$36K – – –
EMG
34
ETF Managers Group
New Jersey
$33K -$2.99K -635 -7%
Bank of America
35
Bank of America
North Carolina
$27K -$47.9K -10,166 -58%
UBS Group
36
UBS Group
Switzerland
$19K -$13.1K -2,780 -34%
TRCT
37
Tower Research Capital (TRC)
New York
$9K -$132K -28,057 -92%
BNP Paribas Financial Markets
38
BNP Paribas Financial Markets
France
$7.33K -$28.2K -5,989 -75%
Royal Bank of Canada
39
Royal Bank of Canada
Ontario, Canada
$7K – – –
ME
40
McIlrath & Eck
Washington
$3K – – –
FCG
41
Financial Connections Group
California
$1K – – –
IA
42
IFP Advisors
Florida
$1K – – –
CAL
43
Capital Advisors Ltd
Ohio
$1K +$984 +209 New
Osaic Holdings
44
Osaic Holdings
Arizona
$1K +$1.41K +300 +600%
Citadel Advisors
45
Citadel Advisors
Florida
– -$455K -80,884 Closed
E
46
Ergoteles
New York
– -$395K -70,114 Closed
CSS
47
Cubist Systematic Strategies
Connecticut
– -$153K -27,251 Closed
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
– -$128K -22,799 Closed
JF
49
Jump Financial
Illinois
– -$104K -18,538 Closed
PP
50
PDT Partners
New York
– -$96K -16,976 Closed
1
2
3

XBIT Hedge Fund Activity: Q3 2022 in Review

45 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q3 2022, worth a combined $11.1M — down 41% from $18.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of XBIT and 5 opened new positions — a net loss of 11 holders — while 17 trimmed existing stakes and 12 added.

The largest buyer was Bridgeway Capital Management, adding an estimated $482K. The largest seller was Millennium Management, cutting an estimated $691K.

  • 45 institutional investors held XBiotech (XBIT) as of Q3 2022, down from 56 in Q2 2022.
  • Funds reported $11.1M of XBiotech stock for Q3 2022, down 41% quarter-over-quarter.
  • 5 funds opened new XBiotech positions in Q3 2022 and 16 closed out, a net change of -11 holders.
  • The largest XBiotech buyer in Q3 2022 was Bridgeway Capital Management, an estimated $482K added.
  • The largest XBiotech seller in Q3 2022 was Millennium Management, an estimated $691K sold.

Based on aggregated 13F filings for Q3 2022.